Overview

Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

Status:
Not yet recruiting
Trial end date:
2024-10-23
Target enrollment:
Participant gender:
Summary
This is a dose exploration study to evaluate the safety and pharmacokinetics (PK) of AZD3152 in healthy adult male and female participants, across different dose levels and routes of administration (ie, Intramuscular [IM] injection and Intravenous [IV] infusion).
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca